Half Yearly Report for period ending 31 December 2025

LTR Pharma has today released its Half Yearly Report for period ending 31 December 2025. 

Key highlights from this period include:  

• US urologists Dr Amy Pearlman and Dr Andrew Sun appointed to Scientific Advisory Board 

• Peer-reviewed publication of Phase I pharmacokinetic data 

• 18-month ICH stability achieved 

• LevOmega equity position increased to ~43%  

• Phase II HREC approval and TGA clinical trial clearance received 

• 1,000+ SPONTAN® SAS prescriptions achieved 

• ROXUS® US launch preparations progressed 

As at 31 December 2025, the Company held a cash balance of A$25.8 million, providing funding runway to execute the SPONTAN Phase II clinical program and support US commercial preparations for ROXUS.  

Click to read the ASX release.